0000899243-21-007438.txt : 20210219 0000899243-21-007438.hdr.sgml : 20210219 20210219185054 ACCESSION NUMBER: 0000899243-21-007438 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210217 FILED AS OF DATE: 20210219 DATE AS OF CHANGE: 20210219 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Thompson Peter A. CENTRAL INDEX KEY: 0001357522 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40030 FILM NUMBER: 21657709 MAIL ADDRESS: STREET 1: C/O ANTHERA PHARMACEUTICALS, INC. STREET 2: 25801 INDUSTRIAL BOULEVARD, SUITE B CITY: HAYWARD STATE: CA ZIP: 94545 FORMER NAME: FORMER CONFORMED NAME: Thompson Peter A DATE OF NAME CHANGE: 20060327 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Decibel Therapeutics, Inc. CENTRAL INDEX KEY: 0001656536 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 464198709 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1325 BOYLSTON STREET STREET 2: SUITE 500 CITY: BOSTON STATE: MA ZIP: 02215 BUSINESS PHONE: 617-370-8701 MAIL ADDRESS: STREET 1: 1325 BOYLSTON STREET STREET 2: SUITE 500 CITY: BOSTON STATE: MA ZIP: 02215 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-02-17 0 0001656536 Decibel Therapeutics, Inc. DBTX 0001357522 Thompson Peter A. C/O DECIBEL THERAPEUTICS, INC. 1325 BOYLSTON STREET, SUITE 500 BOSTON MA 02215 1 0 1 0 Common Stock 2021-02-17 4 C 0 2732106 A 2732106 I See footnote Common Stock 2021-02-17 4 C 0 327852 A 327852 I See footnote Common Stock 2021-02-17 4 C 0 218568 A 218568 I See footnote Common Stock 2021-02-17 4 P 0 1111100 18.00 A 3843206 I See footnote Common Stock 2021-02-17 4 P 0 555566 18.00 A 883418 I See footnote Series D Preferred Stock 2021-02-17 4 C 0 14480162 0.00 D Common Stock 2732106 0 I See footnote Series D Preferred Stock 2021-02-17 4 C 0 1737619 0.00 D Common Stock 327852 0 I See footnote Series D Preferred Stock 2021-02-17 4 C 0 1158412 0.00 D Common Stock 218568 0 I See footnote On February 17, 2021, the Series D Preferred Stock automatically converted into Common Stock on a 5.3-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. These securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. The Reporting Person is an employee of OrbiMed Advisors. By virtue of such relationship, OrbiMed Advisors and GP VIII may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VIII. These securities are held of record by OrbiMed Partners Master Fund Limited ("OPM"). OrbiMed Capital LLC ("OrbiMed Capital") is the investment advisor of OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPM. These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationship, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by Genesis. /s/ Ronald Vigliotta, Attorney-in-Fact 2021-02-19